A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant

This study is researching an experimental drug called linvoseltamab. The study is focused on participants with newly diagnosed multiple myeloma (NDMM) who are ineligible for autologous stem cell transplantation (transplant-ineligible). The main purpose of this study is to compare the effect and safety of linvoseltamab with the effect and safety of the standard treatment.

Trial Details

NCT ID
NCT06932562
Phase
PHASE3
Sponsor
European Myeloma Network B.V.
Status
RECRUITING
Cancer Type
Newly Diagnosed Multiple Myeloma
Interventions
  • Linvoseltamab
  • Daratumumab
  • Lenalidomide
  • Dexamethasone
Locations (sample)
  • Adelaide, Australia|-34.92866,138.59863
  • Box Hill, Australia|-37.81887,145.12545
  • Canberra, Australia|-35.28346,149.12807
  • Geelong, Australia|-38.14711,144.36069
  • Heidelberg, Australia|-37.75,145.06667

Key Eligibility Criteria

  • Participants must have confirmed diagnosis of symptomatic MM per IMWG criteria.
  • Participants must not be considered a candidate for high-dose chemotherapy (HDT) and ASCT, as described in the protocol.
  • Participants must have measurable disease as defined in the protocol.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Newly Diagnosed Multiple Myeloma Trials on Trialify →